sgo 2021 annual meeting: rucaparib vs. chemotherapy in ovarian cancer
Published 3 years ago • 665 plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
2:51
sgo 2021 virtual annual meeting on women’s cancer
-
2:32
sgo 2021 virtual annual meeting: keynote-158 study
-
0:57
sgo 2021 virtual annual meeting: angeles alvarez secord, md
-
0:38
sgo 2021 virtual annual meeting: heidi gray, md
-
1:28
2017 sgo annual meeting | latest research on rucaparib and ovarian cancer
-
3:42
gynecologic oncology at asco 2022: athena–mono trial (rucaparib monotherapy) for ovarian cancer
-
1:00:10
report back from sgo: what’s the latest in ovarian cancer?
-
6:45
2018 sgo annual meeting highlights
-
4:25
gynecologic oncology at esmo congress 2021: randomised phase ii trial of olaparib
-
26:47
2014 society of gynecologic oncology meeting: ovarian cancer
-
5:06
asco22 gynecologic oncology: relacorilant combined with nab-paclitaxel in recurrent ovarian cancer
-
1:37
sgo 2022 annual meeting on the scene: joan walker, md
-
0:46
gynecologic oncology at asco 2022: subgroup analysis of keynote-826
-
1:00:51
report back from sgo: what's the latest in ovarian cancer?
-
3:45
sgo 2022 annual meeting on the scene: bernadette cracchiolo, md, mph, facog, faahpm, fabpm
-
3:21
sgo 2022 annual meeting on women's cancer inspirational open
-
2:15
toxicities associated with rucaparib for the treatment of ovarian cancer
-
1:44
the delivery of niraparib and rucaparib as ovarian cancer treatment options
-
1:15
2017 sgo annual meeting | ovarian cancer surgery and hospital readmissions